137 related articles for article (PubMed ID: 30367508)
1. Inactivation of ATF-2 enhances epithelial-mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer cells.
Wu X; Liu Z; Guo K; Ma G; Song S
J Cell Biochem; 2019 Mar; 120(3):4463-4471. PubMed ID: 30367508
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
3. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
Wang R; Cheng L; Xia J; Wang Z; Wu Q; Wang Z
Curr Cancer Drug Targets; 2014; 14(4):407-17. PubMed ID: 24575976
[TBL] [Abstract][Full Text] [Related]
5. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
[TBL] [Abstract][Full Text] [Related]
6. Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.
Chen S; Wang Y; Zhang WL; Dong MS; Zhang JH
Mol Med Rep; 2017 Apr; 15(4):1461-1470. PubMed ID: 28259943
[TBL] [Abstract][Full Text] [Related]
7. Catechol enhances chemo‑ and radio‑sensitivity by targeting AMPK/Hippo signaling in pancreatic cancer cells.
Moon JY; Ediriweera MK; Ryu JY; Kim HY; Cho SK
Oncol Rep; 2021 Mar; 45(3):1133-1141. PubMed ID: 33650657
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition.
Quint K; Tonigold M; Di Fazio P; Montalbano R; Lingelbach S; Rückert F; Alinger B; Ocker M; Neureiter D
Int J Oncol; 2012 Dec; 41(6):2093-102. PubMed ID: 23026911
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
Yao J; Qian C
Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of LOXL2 in pancreatic carcinoma.
Rückert F; Joensson P; Saeger HD; Grützmann R; Pilarsky C
Int J Colorectal Dis; 2010 Mar; 25(3):303-11. PubMed ID: 20012301
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.
Zhao H; Duan Q; Zhang Z; Li H; Wu H; Shen Q; Wang C; Yin T
J Cell Mol Med; 2017 Sep; 21(9):2055-2067. PubMed ID: 28244691
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
15. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.
El Amrani M; Corfiotti F; Corvaisier M; Vasseur R; Fulbert M; Skrzypczyk C; Deshorgues AC; Gnemmi V; Tulasne D; Lahdaoui F; Vincent A; Pruvot FR; Van Seuningen I; Huet G; Truant S
Mol Carcinog; 2019 Nov; 58(11):1985-1997. PubMed ID: 31373074
[TBL] [Abstract][Full Text] [Related]
17. Silencing of ATF2 inhibits growth of pancreatic cancer cells and enhances sensitivity to chemotherapy.
Li M; Wu X; Liu N; Li X; Meng F; Song S
Cell Biol Int; 2017 Jun; 41(6):599-610. PubMed ID: 28318081
[TBL] [Abstract][Full Text] [Related]
18. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
19. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.
Funamizu N; Hu C; Lacy C; Schetter A; Zhang G; He P; Gaedcke J; Ghadimi MB; Ried T; Yfantis HG; Lee DH; Subleski J; Chan T; Weiss JM; Back TC; Yanaga K; Hanna N; Alexander HR; Maitra A; Hussain SP
Int J Cancer; 2013 Feb; 132(4):785-94. PubMed ID: 22821831
[TBL] [Abstract][Full Text] [Related]
20. YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells.
Yuan Y; Li D; Li H; Wang L; Tian G; Dong Y
Mol Med Rep; 2016 Jan; 13(1):237-42. PubMed ID: 26572166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
